{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Anaplastic+Ependymoma&page=2",
    "query": {
      "condition": "Adult Anaplastic Ependymoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Anaplastic+Ependymoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T21:35:33.103Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00110032",
      "title": "Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Central Nervous System Germ Cell Tumor",
        "Adult Choroid Plexus Tumor",
        "Adult Craniopharyngioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Ependymoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Grade III Meningioma",
        "Adult Medulloblastoma",
        "Adult Meningeal Hemangiopericytoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Pineoblastoma",
        "Adult Pineocytoma",
        "Adult Subependymoma",
        "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)",
        "Meningeal Melanocytoma"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "fluorine F 18 EF5",
          "type": "RADIATION"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110032"
    },
    {
      "nct_id": "NCT05057702",
      "title": "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Medulloblastoma",
        "Medulloblastoma, Childhood",
        "Medulloblastoma Recurrent",
        "Ependymoma",
        "Ependymoma Malignant",
        "Ependymoma of Brain"
      ],
      "interventions": [
        {
          "name": "Specialized Tumor Board Treatment Plan",
          "type": "OTHER"
        },
        {
          "name": "Combinations",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "12 Months to 39 Years"
      },
      "enrollment_count": 74,
      "start_date": "2022-02-22",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05057702"
    },
    {
      "nct_id": "NCT00008086",
      "title": "Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "calcitriol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1996-01",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008086"
    },
    {
      "nct_id": "NCT01125046",
      "title": "Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acoustic Schwannoma",
        "Adult Anaplastic Meningioma",
        "Adult Ependymoma",
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Meningeal Hemangiopericytoma",
        "Adult Papillary Meningioma",
        "Neurofibromatosis Type 1",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2010-06-17",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125046"
    },
    {
      "nct_id": "NCT01462695",
      "title": "Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Cerebellar Anaplastic Astrocytoma",
        "Childhood Cerebral Anaplastic Astrocytoma",
        "Childhood Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Mixed Glioma",
        "Childhood Oligodendroglioma",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Diagnostic Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-27",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01462695"
    },
    {
      "nct_id": "NCT01082926",
      "title": "Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Ependymoma",
        "Anaplastic Meningioma",
        "Anaplastic Oligodendroglioma",
        "Brain Stem Glioma",
        "Ependymoblastoma",
        "Giant Cell Glioblastoma",
        "Glioblastoma",
        "Gliosarcoma",
        "Grade III Meningioma",
        "Meningeal Hemangiopericytoma",
        "Mixed Glioma",
        "Pineal Gland Astrocytoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-05",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082926"
    },
    {
      "nct_id": "NCT01480050",
      "title": "Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3'-deoxy-3'-[18F]fluorothymidine",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "Mibefradil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-05-31",
      "completion_date": "2017-06-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01480050"
    },
    {
      "nct_id": "NCT00274755",
      "title": "Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance spectroscopic imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2003-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274755"
    },
    {
      "nct_id": "NCT04541082",
      "title": "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Glioblastoma",
        "Gliosarcoma, Adult",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Astrocytoma",
        "Pilocytic Astrocytoma",
        "Oligodendroglioma",
        "Gliomatosis Cerebri",
        "Pleomorphic Xanthoastrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Ependymoma",
        "Ependymoma, Anaplastic",
        "Medulloblastoma",
        "Teratoid Rhabdoid Tumor",
        "Neuroectodermal Tumors, Primitive",
        "Neuroectodermal Tumors",
        "Anaplastic Meningioma",
        "Atypical Meningioma",
        "Choroid Plexus Neoplasms",
        "Pineal Tumor",
        "Diffuse Astrocytoma",
        "Glial Tumor"
      ],
      "interventions": [
        {
          "name": "ONC206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-10-26",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541082"
    },
    {
      "nct_id": "NCT01996527",
      "title": "3T MRI Biomarkers of Glioma Treatment Response",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "3-Tesla magnetic resonance imaging",
          "type": "DEVICE"
        },
        {
          "name": "CEST-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DW-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DCE-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DSC-MRI",
          "type": "DEVICE"
        },
        {
          "name": "IV administration of gadolinium-containing contrast agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2012-05",
      "completion_date": "2016-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-05-21T21:35:33.103Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996527"
    }
  ]
}